TScan Therapeutics (TCRX) Other Non-Current Liabilities (2020 - 2025)
TScan Therapeutics (TCRX) posted quarterly Other Non-Current Liabilities of $278000.0 for Q3 2025, up 90.41% year-over-year from $146000.0 in Q3 2024, and up 146.02% quarter-over-quarter from $113000.0 in Q2 2025.
TScan Therapeutics (TCRX) Other Non-Current Liabilities (2020 - 2025) Analysis & Trends
TScan Therapeutics (TCRX) has reported Other Non-Current Liabilities for 6 consecutive years, with $278000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Other Non-Current Liabilities rose 90.41% year-over-year to $278000.0; the TTM figure through Sep 2025 stood at $278000.0 (up 90.41% YoY), while the FY2024 annual figure was $135000.0, changed N/A from the prior year.
- Other Non-Current Liabilities climbed to $278000.0 in Q3 2025 per TCRX's latest filing, from $113000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $278000.0 in Q3 2025 and bottomed at $12000.0 in Q3 2023.
- Historically, Other Non-Current Liabilities has averaged $118600.0 across 5 years, with a median of $97000.0 in 2021.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities tumbled 87.63% — and 2024, when it soared 1116.67%.
- TScan Therapeutics' Other Non-Current Liabilities stood at $97000.0 in 2021, then plunged by 49.48% to $49000.0 in 2022, then slumped by 75.51% to $12000.0 in 2023, then soared by 1025.0% to $135000.0 in 2024, then jumped by 105.93% to $278000.0 in 2025.
- Business Quant data shows TCRX's Other Non-Current Liabilities at $278000.0 in Q3 2025, $113000.0 in Q2 2025, and $124000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 278,000.00 |
| Jun 30, 2025 | 113,000.00 |
| Mar 31, 2025 | 124,000.00 |
| Dec 31, 2024 | 135,000.00 |
| Sep 30, 2024 | 146,000.00 |
| Sep 30, 2023 | 12,000.00 |
| Jun 30, 2023 | 24,000.00 |
| Mar 31, 2023 | 36,000.00 |
| Dec 31, 2022 | 49,000.00 |
| Sep 30, 2022 | 97,000.00 |
| Jun 30, 2022 | 97,000.00 |
| Mar 31, 2022 | 97,000.00 |
| Dec 31, 2021 | 97,000.00 |
| Sep 30, 2021 | 236,000.00 |
| Jun 30, 2021 | 238,000.00 |
| Dec 31, 2020 | 238,000.00 |